

Participation Virtual ESMO 2020

Special session - 1

"Established and new treatments, old and new toxicities (in collaboration with MASCC)"

Speaker : **Dr Vincent Sibaud** "Skin toxicity: More than just a rash"

Proffered paper session - 11

LBA41 - LEAP-005: Phase 2 Study of Lenvatinib (Len) Plus Pembrolizumab (Pembro) in Patients (Pts) With Previously Treated Advanced Solid Tumors

Z. Lwin 1, **C. Gomez-Roca** 2, E. Saada-Bouid 3, E. Yanez 4, F. Longo Muñoz 5, S.-A. Im6, E. Castanon 7, H. Senellart 8, D. Graham9, M. Voss 10, M. Doherty 11, J. Lopez 12, R. Ghori 13, P. Kubiak 14, F. Jin 13, K. Norwood 13, H.C. Chung 15

12140 - NEOADJUVANT DURVALUMAB IN RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY RESULTS FROM A MULTICENTER STUDY (IFCT-1601 IONESCO)

M. Wislez 1, **J. Mazieres** 2, A. Lavole 1, G. Zalcman 3, O. Carre 4, T. Egenod 5, R. Caliendo 6, R. Gervais 7, G. Jeannin 8, O. Molinier 9, M.A. Massiani 10, A. Langlais 11, F. Morin 12, F. Le Pimpec Barthes 13, L. Brouchet 2, J. Assouad 14, B. Milleron 12, D. Damotte 15, M. Antoine 1, V. Westeel 16

LBA38 - PEMBROLIZUMAB VERSUS CETUXIMAB, CONCOMITANT WITH RADIOTHERAPY (RT) IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (LA-HNSCC): RESULTS OF THE GORTEC 2015-01 "PEMBRORAD" RANDOMIZED TRIAL

Y. Tao 1, X. Sun 2, C. Sire 3, L. Martin 4, M. Alfonsi 5, J.B. Prevost 6, **M. Rives** 7, C. Lafond 8, J.M. Tourani 9, J. Biau 10, L. Geoffrois 11, A. Coutte 12, X. Liem13, E. Vauleon 14, F. Drouet 15, A. Pechery 16, J. Guigay 17, M. Wanneveich 16, A. Aupérin 1, J. Bourhis 18

LBA39 - 3-YEARS FOLLOW-UP OF DOUBLE-BLIND RANDOMIZED PHASE II COMPARING CONCURRENT HIGH-DOSE CISPLATIN CHEMO-RADIATION PLUS DEBIO-1143 (XEVINAPANT) OR PLACEBO IN HIGH-RISK PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

J. Bourhis 1, X. Sun 2, C. Le Tourneau 3, Y. Pointreau 4, C. Sire 5, M.-C. Kaminsky-Forrett 6, A. Coutte 7, M. Alfonsi 8, P. Boisselier 9, L. Martin 10, **J.-P. Delord** 11, F. Clatot 12, J. Biau 13, F. Rolland 14, K. Gollmer 15, S. Szyldergemajn 15, C. Even 16, Y. Tao 16

LBA2 - LORLATINIB VS CRIZOTINIB IN THE FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC): RESULTS OF THE PHASE 3 CROWN STUDY

B. Solomon 1, T. Bauer 2, F. De Marinis 3, E. Felip 4, Y. Goto 5, G. Liu 6, **J. Mazieres** 7, D.-W. Kim8, T. Mok 9, A. Polli 10, H. Thurm11, A.M. Calella 12, G. Peltz 13, A. Shaw14

LBA68 - RESULTS OF THE RANDOMIZED, PLACEBO (PL)-CONTROLLED PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF REGORAFENIB (REG) IN PATIENTS (PTS) WITH METASTATIC RELAPSED EWING SARCOMA (ES), ON BEHALF OF THE FRENCH SARCOMA GROUP LAST UPDATE: 09-09-2020 02:43:20PM PROGRAMME (FSG) AND UNICANCER

F. Duffaud 1, J.-Y. Blay 2, O. Mir 3, **C. Chevreau** 4, P. Boudou Rouquette 5, E. Kalbacher 6, N. Penel 7, C. Perrin 8, V. Laurence 9, E. Bompas 10, E. Saada-Bouid 11, C. Delcambre 12, F. Bertucci 13, M. Cancel 14, C. Schiffler 2, L. Monard 15, C. Bouvier 16, V. Vidal 16, N. Gaspar 3, S. Chabaud 2

LBA53 - PRECISION IMMUNO-ONCOLOGY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS) TREATED WITH PD1/L1 IMMUNE CHECKPOINT INHIBITORS (ICIS): A FIRST ANALYSIS OF THE PIONEER STUDY

F. Barlesi 1, L. Greillier 2, F. Monville 3, C. Foa 4, J. Le Treut 5, C. Audigier-Valette 6, F. Vély 7, S. Garcia 8, F. Sabatier 9, J.

Ciccolini 10, M. Fabre 7, M. Le Ray 11, N. Resseguier 8, P. Outters 3, M. Roumieux 12, J. Mazieres 13, M. Pérol 14, E. Vivier 10, P. Auquier 8, J. Fieschi 3

7000 - KIDNEY CCRCC IMMUNE CLASSIFICATION (KIC) ENHANCES THE PREDICTIVE VALUE OF T EFFECTOR (TEFF) AND ANGIOGENESIS (ANGIO) SIGNATURES IN RESPONSE TO NIVOLUMAB (N)

M. Meylan 1, B. Beuselinck 2, C. Dalban 3, Y. Vano 4, N. Rioux Leclercq 5, C. Sautès-Fridman 1, E. Roussel 6, A. Verbiest 7, N. Chaput 8, S. Terry 9, C. Chevreau 10, M. Gross Goupil 11, A. Fléchon 12, B. Laguerre 13, S. Chabaud 3, F. Tantot 14, D. Lambrechts 2, B. Escudier 15, W.-H. Fridman 1, L. Albiges 16

LBA25 - RESULTS FROM THE PHASE 2 BIOMARKER DRIVEN TRIAL WITH NIVOLUMAB (N) AND IPILIMUMAB OR VEGFR TYROSINE KINASE INHIBITOR (TKI) IN NAÏVE METASTATIC KIDNEY CANCER (M-CCRCC) PATIENTS (PTS): THE BIONIKK TRIAL.

Y. Vano 1, R. Elaidi 2, M. Bennamoun 3, C. Chevreau 4, D. Borchellini 5, D. Pannier 6, D. Maillet 7, M. Gross-Goupil 8, C. Tournigand 9, B. Laguerre 10, P. Barthélémy 11, F. Joly 12, G. Gravis 13, S. Caruso 14, C.-M. Sun 14, V. Verkarre 15, W.-H. Fridman 16, J. Zucman-Rossi 17, C. Sautès-Fridman 16, S. Oudard 1

LBA24 - TROPHY-U-01 COHORT 1 FINAL RESULTS: A PHASE 2 STUDY OF SACITUZUMAB GOVITECAN (SG) IN METASTATIC UROTHELIAL CANCER (MUC) THAT HAS PROGRESSED AFTER PLATINUM (PLT) AND CHECKPOINT INHIBITORS (CPI)

Y. Lorient 1, A. Balar 2, D. Petrylak 3, S. Tagawa 4, A. Rezazadeh 5, A. Fléchon 6, R. Jain 7, N. Agarwal 8, M. Bupathi 9, P. Barthélémy 10, P. Beuzeboc 11, P. Palmos 12, C. Kyriakopoulos 13, D. Pouessel 14, C. Sternberg 15, Q. Hong 16, T. Goswami 16, L. Itri 16, P. Grivas 17,

5260 - HIGH ACTIVITY OF NIVOLUMAB IN PATIENTS WITH PATHOGENIC EXONUCLEASIC DOMAIN POLE (EDPOLE) MUTATED MISMATCH REPAIR PROFICIENT (MMRP) ADVANCED TUMOURS

B. Rousseau 1, I. Bieche 2, E. Pasmant 3, V. Simmet 4, N. Hamzaoui 3, J. Masliah-Planchon 2, D. Pouessel 5, A. Bruyas 6, P. Augereau 4, J.-J. Grob 7, F. Rolland 8, E. Saada-Bouزيد 9, R. Cohen 10, O. Bouche 11, N. Hoog-Labouret 12, F. Legrand 13, C. Simon 14, A. LamraniGhaoui 14, S. Chevret 15, A. Marabelle 16

Posters sessions - 33

OLIGOMETASTATIC BREAST CANCER INCIDENCE AND CLINICAL PRESENTATION AT DIAGNOSIS: ABOUT 131 CASES

J.L. Lacaze 1, C. Chira, G. Glemarec, R. Aziza, E. De Maio, F. Izar, E. Jouve, C. Massabeau, A. Pradines, G. Selmes, M. Ung, S. Zerdoud, F. Dalenc

[Lire](#)

TEPOTINIB IN PATIENTS (PTS) WITH ADVANCED NSCLC WITH MET EXON 14 (METEX14) SKIPPING: OVERALL EFFICACY RESULTS FROM VISION COHORT A

J. Mazieres 1, P.K. Paik2, E. Felipe3, R. Veillon4, H. Sakai5, A.B. Cortot6, S. Viteri7, M.C. Garassino8, J.P. Van Meerbeeck9, J. Raskin9, M. Thomas10, M. Morise11, B.C. Cho12, P. Conte13, R. Bruns14, T. Demuth15, K.M. Schumacher15, X. Le16

[Lire](#)

IMPACT OF KRAS MUTATIONS AND SUBTYPES ON EFFICACY OF IMMUNE-CHECKPOINT INHIBITORS (ICI) IN NON-SMALL CELL LUNG CANCER (NSCLC)

J. Mazieres 1, P. Tomasini2, A. Lusque3, M. Boucekine2, O. Gautschi4, A.B. Cortot5, S. Couraud6, A. Thai7, T. Ng8, L. Greillier9, R. Veillon10, J.W. Neal11, S. Popat12, V. Gounant13, L. Mhanna1, A. Drilon14, J. Milia Baron1, F. Barlesi15

[Lire](#)

PEMBROLIZUMAB (PEMBRO) PLUS ENZALUTAMIDE (ENZA) IN PATIENTS WITH ABIRATERONE ACETATE (ABI)-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): KEYNOTE-365 COHORT C UPDATE

L. Mourey 1, H.J. Conter2, N. Shore3, W.R. Berry4, P.C. Fong5, J.M. Piulats6, L.J. Appleman7, T. Todenhöfer8, G. Gravis9, B. Laguerre10, H. Gurney11, M. Retz12, E. Romano13, J.S. de Bono14, A.E. Kam15, U. Emmenegger16, H. Wu17, P. Qiu17, C. Schloss17, E.Y. Yu18

[Lire](#)

4-YEAR SURVIVAL IN RANDOMISED PHASE II (POPLAR) AND PHASE III (OAK) STUDIES OF ATEZOLIZUMAB (ATEZO) VS DOCETAXEL (DOC) IN PRE-TREATED NSCLC

J. Mazieres¹, A. Rittmeyer², S.M. Gadgil³, T. Hida⁴, D. Gandara⁵, D. Cortinovis⁶, F. Barlesi⁷, W. Yu⁸, C. Matheny⁹, M. Ballinger⁹, K. Park¹⁰

[Lire](#)

CLINICAL RELEVANCE OF MIR27A RS895819 POLYMORPHISM AND ITS INTERACTION WITH DPYD VARIANTS FOR PREDICTING GRADE 4-5 FLUOROPYRIMIDINE (FP) TOXICITY (TOX) IN THE FUSAFE INDIVIDUAL PATIENT DATA META-ANALYSIS (IPD-MA)

Avec **Fabienne Thomas**, co-auteur

BALSTILIMAB (ANTI-PD-1) ALONE AND IN COMBINATION WITH ZALIFRELIMAB (ANTI-CTLA-4) FOR RECURRENT/METASTATIC (R/M) CERVICAL CANCER (CC) PRELIMINARY RESULTS OF TWO INDEPENDENT PH2 TRIALS (NCT03104699 AND NCT03495882)

Avec le **Dr Laurence Gladieff**, co-auteur

ACTIVITY OF LURBINECTEDIN IN SECOND-LINE SCLC PATIENTS CANDIDATES FOR PLATINUM RE-CHALLENGE

V. Subbiah¹, L. Paz-Ares², B. Besse³, V. Moreno Garcia⁴, K. Zaman⁵, M.A. Sala Gonzalez⁶, J.A. Lopez-Vilarino⁷, C.M. Fernandez⁷, C. Kahatt⁷, M. Sigüero⁷, A. Zeaiter⁷, R. Lopez Lopez⁸, S. Ponce Aix², V. Boni⁹, J. Arrondeau¹⁰, **J.P. Delord**¹¹, M. Martínez-Aguillo¹², L. Wannesson De Nicola¹³, A. Anton Torres¹⁴, J.M. Trigo Perez¹⁵

[Lire](#)

DESMOID TYPE FIBROMATOSIS IN PATIENTS

S. Bouttefroy¹, N. Penel², V. Minard-Colin³, D. Orbach⁴, A. Le Cesne⁵, J. Blay⁶, P. Marec Berard¹, C. Verité⁷, V. Laurence⁴, S. Piperno-Neumann⁴, A. Defachelles⁸, E. Bompas⁹, **C.M. Chevreau**¹⁰, F. Duffaud¹¹, S. Salas¹², M. Morelle¹³, M. Jean Denis¹³, A. Italiano¹⁴, S. Bonvalot¹⁵, N. Corradini¹

[Lire](#)

METASYN: PATTERNS OF CARE AND OUTCOMES OF 387 METASTATIC SYNOVIAL SARCOMA: REAL-LIFE DATA FROM THE FRENCH SARCOMA GROUP (GSF/GETO)

C. Moreau-bachelard¹, M. Toulmonde², A. Le Cesne³, M. Brahmi⁴, A. Italiano⁵, O. Mir⁶, S. Piperno-Neumann⁷, V. Laurence⁷, N. Firmin⁸, **C.M. Chevreau**⁹, F. Bertucci¹⁰, B. Narciso¹¹, P. Dubray-Longeras¹², C. Delcambre¹³, E. Saada-Bouid¹⁴, P. Soulié¹⁵, C. Perrin¹⁶, J. Blay¹⁷, E. Bompas¹⁸

[Lire](#)

PHASE IB/II OPEN-LABEL, RANDOMISED EVALUATION OF ATEZOLIZUMAB (ATEZO) + CPI-444 VS DOCETAXEL AS SECOND/THIRD-LINE THERAPY IN MORPHEUS-NSCLC (NON-SMALL CELL LUNG CANCER)

E. Felip¹, F.L. Lim², M. Johnson³, M. O'Brien⁴, F. Barlesi⁵, **J. Mazieres**⁶, B. Solomon⁷, V. Moreno Garcia⁸, V. Boni⁹, A. Swaldus¹⁰, S. Goldberg¹¹, B. Keam¹², S. Allen¹³, H. Helms¹⁴, C. Shemesh¹⁵, J. Pintoff¹⁶, N. Al-Sakaff¹⁷, L. Bailey¹⁸, P. Sayyed¹⁷, B.C. Cho¹⁹

[Lire](#)

LORLATINIB FOR ADVANCED ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY AND SAFETY DATA FROM IFCT-1803 LORLATU EXPANDED ACCESS PROGRAM (EAP) COHORT

S. Baldacci¹, B. Besse², V. Avrillon³, B. Menecier⁴, P. Dubray-Longeras⁵, **J. Mazieres**⁶, R. Descourt⁷, M. Duruisseaux⁸, X. Quantin⁹, H. Doubre¹⁰, I. Monnet¹¹, D. Moro-Sibilot¹², S. Schneider¹³, S. Cousin¹⁴, P. Merle¹⁵, J. Otto¹⁶, A. Langlais¹⁷, F. Morin¹⁸, V. Westeel¹⁹, N. Girard²⁰

[Lire](#)

ACTIVITY OF TEPOTINIB IN BRAIN METASTASES (BM): PRECLINICAL MODELS AND CLINICAL DATA FROM PATIENTS (PTS) WITH MET EXON 14 (METEX14) SKIPPING NSCLC

S. Viteri¹, **J. Mazieres**², R. Veillon³, E. Felip⁴, X. Le⁵, M.C. Garassino⁶, T.S. Stanton⁷, M. Morise⁸, J. Lee⁹, S. Matsumoto¹⁰, F. De Marinis¹¹, T. Wehler¹², A. Clark¹³, M. Friesse-Hamim¹⁴, C. Stroh¹⁴, R. Bruns¹⁵, G. Otto¹⁶, P.K. Paik¹⁷

[Lire](#)

DURVALUMAB (D) COMPARED TO MAINTENANCE CHEMOTHERAPY (SOC) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): RESULTS FROM THE RANDOMIZED SAFIRO2 LUNG-IMMUNO TRIAL

F. Barlesi¹, M. KARIMI², P. Tomasini³, C. Daniel⁴, J. Raimbourg⁵, A. Quoix⁶, A. Madroszyk Flandin⁷, **J. Mazieres**⁸, O. Molinier⁹, C. Audigier-Valette¹⁰, D. Moro-Sibilot¹¹, H. Morel¹², P. Souquet¹³, I. Bieche¹⁴, A. TRAN-DIEN¹⁵, A. Jacquet¹⁶, J. Adam¹⁷, J. Soria¹, B. Besse¹⁸

[Lire](#)

LANREOTIDE AS MAINTENANCE THERAPY AFTER FIRST-LINE TREATMENT IN PATIENTS WITH NON-RESECTABLE DUODENO-PANCREATIC NEUROENDOCRINE TUMOURS (NETS): AN INTERNATIONAL DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED PHASE II TRIAL

C. Lepage¹, J.M. Phelip², A. LIÈVRE³, K. Le Malicot⁴, D. Tougeron⁵, L. Dahan⁶, C. Toumpanakis⁷, F. Di Fiore⁸, C. Lombard Bohas⁹, I. Borbath¹⁰, R. Coriat¹¹, M. Caulet¹², R. Guimbaud¹³, C. Petorin¹⁴, J.L. Legoux¹⁵, J. Scoazec¹⁶, P. Michel¹⁷, G. Cadot¹⁸, D. Smith¹⁹, T. Walter²⁰

[Lire](#)

A DIGITAL COMPANION FOR PATIENTS WITH BRAF-MUTANT ADVANCED MELANOMA TREATED WITH TARGETED THERAPIES: TAVIE SKIN APP

P. Mohr¹, A. Tadmouri², J. Suissa³, M. Alivon⁴, N. Meyer⁵

[Lire](#)

FACTORS PREDICTING OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) IN REAL-LIFE: CLASSIFICATION AND REGRESSION TREE ANALYSIS OF A 5-YEAR (5Y) COHORT FOLLOW-UP STUDY OF ADVANCED MELANOMA PATIENTS (PTS) THAT HAVE INITIATED PEMBROLIZUMAB

P. Saiag¹, N. Meyer², C. Dutriaux³, L. Verdoni⁴, O. Morsli⁴, A. Spampinato⁵, L. Lattenist⁶, L. Mortier⁷, J. Grob⁸

[Lire](#)

CEMIPLIMAB FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA: REAL LIFE EXPERIENCE

C. Hober¹, L. Fredeau², A. Pham Ledard³, M. Boubaya⁴, F. Herms⁵, F. Aubin⁶, N. Benetton⁷, M. Dinulescu⁸, A. Jannic⁹, L. Cesaire¹⁰, N. Meyer¹¹, A.B. Duval Modeste¹², E. Archier¹³, C. Lesage¹⁴, N. Kramkimel¹⁵, J.P. Arnault¹⁶, F. Grange¹⁷, S. Dalac¹⁸, L. Mortier¹⁹, E. Maubec²⁰

[Lire](#)

THE IMPACT OF PATIENTS' AND PHYSICIANS' CHARACTERISTICS ON SURGERY DECISION FOR HEAD AND NECK CANCER: RESULTS OF A NATIONAL SURVEY

F. Cros¹, S. Lamy², P. Grosclaude³, A. Nebout⁴, P. Bories⁵, A. Dupret-Bories⁶

[Lire](#)

FIRST REAL-LIFE DATA ON OLAPARIB IN 1ST LINE (1STL) MAINTENANCE BRCA1/2 MUTATED EPITHELIAL OVARIAN CANCER (EOC) IN FRANCE: DESCRIPTIVE ANALYSIS OF 201 PATIENTS (PTS) ENROLLED IN THE COHORT TEMPORARY AUTHORIZATION FOR USE (ATUC)

C. Bellier¹, L. Gladieff², F. Le Du³, C. Garnier Tixidre⁴, D. Berton-Rigaud⁵, C. Bonnard⁶, A. Lahrache⁶, A. Debbache⁶, A. Kacher-Damache⁶, M. Delplanque⁷, D. Suau⁷, A. Richard⁸, O. Brenner⁷, A. Lahouegue⁸, M. Urbiet⁹, C. Gavaille¹⁰, G. Freyer¹¹, A. Floquet¹², S. Frank¹³, M. Kfoury¹⁴

[Lire](#)

URACHAL CARCINOMA: LARGE RETROSPECTIVE MULTICENTRIC GETUG-AFU STUDY

M. Guerin¹, E. Colomba-Blameble², C. Miran³, T. HERRMANN⁴, S. Pericart⁵, D. Maillet⁶, Y. Neuzillet⁷, A. DELEUZE⁸, C. Thibault⁹, E. Coquan¹⁰, C. Dumont¹¹, E. Boughalem¹², D. Borchellini¹³, B. Mesnard¹⁴, A. Khalil¹⁵, G. Baciarello², A. Fléchon¹⁶, J. Walz¹⁷, G. Gravis¹⁸

[Lire](#)

CABOZANTINIB IN NON-CLEAR CELL METASTATIC RENAL CELL CARCINOMA AND SARCOMATOID RENAL CELL CARCINOMA: REAL-WORLD DATA FROM THE CABOREAL STUDY

A. Fléchon¹, C.M. Chevreau², D. Topart³, G. Gravis⁴, S. Oudard⁵, J.M. Tourani⁶, L. Geoffrois⁷, E. Meriaux⁸, A. Thiery-Vuillemin⁹, P. Barthélémy¹⁰, S. Ladoire¹¹, B. Laguerre¹², R. Bourouina¹³, V. Perrot¹³, B. Escudier¹⁴, M. Gross-Goupil¹⁵, L. Albiges¹⁶

[Lire](#)

A PROSPECTIVE PHASE II STUDY OF GEMCITABINE PLUS PLATINUM IN COMBINATION WITH BEVACIZUMAB FOR METASTATIC RENAL MEDULLARY AND COLLECTING DUCT CARCINOMA (GETUG-AFU 24, BEVABEL TRIAL)

C. Thibault¹, R.T. Elaidi², A. Fléchon³, L. Albiges⁴, C. Joly⁵, P. Barthélémy⁶, M. Gross Goupil⁷, C.M. Chevreau⁸, F. Joly⁹, F. Rolland¹⁰, B. Laguerre¹¹, G. Gravis¹², M. Brihoum¹³, M. Timsit¹⁴, N. Pecuchet¹, Y. Allory¹⁵, S. Oudard¹⁶

[Lire](#)

CABOZANTINIB IN ELDERLY PATIENTS: RESULTS FROM A SUBANALYSIS OF THE CABOREAL STUDY

M. Gross-Goupil¹, A. Fléchon², **L. Mourey**³, D. Topart⁴, G. Gravis⁵, S. Oudard⁶, J.M. Tourani⁷, L. Geoffrois⁸, E. Meriaux⁹, A. Thiery-Vuillemin¹⁰, P. Barthélémy¹¹, S. Ladoire¹², B. Laguerre¹³, R. Bourouina¹⁴, V. Perrot¹⁴, B. Escudier¹⁵, L. Albiges¹⁵
[Lire](#)

PRIMARY TUMOUR RESPONSE IN PATIENTS TREATED WITH NIVOLUMAB FOR METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS OF THE GETUG-AFU 26 NIVOREN TRIAL

J. Courcier¹, C. Dalban², B. Laguerre³, S. Ladoire⁴, P. Barthélémy⁵, S. Oudard⁶, F. Joly⁷, G. Gravis Mescam⁸, **C.M. Chevreau**⁹, L. Geoffrois¹⁰, E. Deluche¹¹, F. Rolland¹², D. Topart¹³, S. Culine¹⁴, S. Négrier¹⁵, H. Mahammedi¹⁶, F. Tantot¹⁷, B. Escudier¹⁸, R. Flippot¹⁹, L. Albiges¹⁸
[Lire](#)

PEMBROLIZUMAB (PEMBRO) PLUS DOCETAXEL AND PREDNISONE IN PATIENTS WITH ABIRATERONE ACETATE (ABI)- OR ENZALUTAMIDE (ENZA)–PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): KEYNOTE-365 COHORT B UPDATE

E. Romano¹, S.S. Sridhar², M.P. Kolinsky³, G. Gravis⁴, **L. Mourey**⁵, J.M. Piulats⁶, W.R. Berry⁷, H. Gurney⁸, M. Retz⁹, L.J. Appleman¹⁰, M. Boegemann¹¹, J.S. de Bono¹², A.M. Joshua¹³, U. Emmenegger¹⁴, H.J. Conter¹⁵, B. Laguerre¹⁶, H. Wu¹⁷, P. Qiu¹⁷, C. Schloss¹⁷, E.Y. Yu¹⁸
[Lire](#)

SAFETY AND EFFICACY OF DEBIO 1143, AN ANTAGONIST OF INHIBITOR OF APOPTOSIS PROTEINS (IAPS), IN COMBINATION WITH NIVOLUMAB IN A PHASE IB/II TRIAL IN PATIENTS (PTS) FAILING PRIOR PD-1/PD-L1 TREATMENT

A.B. Azaro Pedrazzoli¹, V. Moreno Garcia², **C.A. Gomez-Roca**³, C. Even⁴, P. Cassier⁵, T.C. Hernandez Guerrero², M. de Miguel⁶, **I. Korakis**³, D. Purcea⁷, E. Roy⁷, K. Gollmer⁷, C. Riff⁷, S.A. Szyldergemajn⁷, E. Calvo⁶
[Lire](#)

VEMURAFENIB IN NON-MELANOMA V600 AND NON-V600 BRAF MUTATED CANCERS: RESULTS OF THE ACSÉ BASKET TRIAL

P. Tomasini¹, **J. Mazieres**², C. Cropet³, X.G. Troussard⁴, D. Malka⁵, I.L. Ray-Coquard⁶, S. Leboulleux⁷, A. Fléchon⁸, B. Arnulf⁹, M. Cancel¹⁰, I. Bieche¹¹, S. Collot¹², S. Taieb¹³, G. Garcia¹⁴, A. Mandache¹⁵, N. Colignon¹⁶, M. Gavrel¹⁴, M. Jimenez¹⁷, N. Hoog-Labouret¹⁸, J. Blay⁶
[Lire](#)

BEVACIZUMAB (BEV) CONTINUATION WITH FOLFIRI OR SWITCH TO AFLIBERCEPT (AFLI) WITH FOLFIRI AS SECOND-LINE TREATMENT (L2) AFTER FIRST LINE OF FOLFOX-BEV (L1) FOR METASTATIC COLORECTAL CANCER (MCR): AN AGEO MULTICENTER STUDY

C. Torregrosa¹, S. Pernot², A. Perret³, V. Randrian⁴, S. Racine Doat⁵, B. Auberger⁶, T. Godet⁷, **M. Jaffrelot**⁸, O. Dubreuil⁹, A. Turpin¹⁰, L. Palmieri¹¹, O. Bouche¹², T. Lecomte¹³, D. Sefrioui¹⁴, C. Locher¹⁵, C. Neuzillet¹⁶, E. Nassif¹⁷, C. Lecaille¹⁸, J. Taieb¹, E. Auclin¹
[Lire](#)

REAL-LIFE MANAGEMENT AND PROGNOSIS OF YOUNG WOMEN (≤ 40 YO) WITH DE NOVO METASTATIC BREAST CANCER IN THE MULTICENTER NATIONAL OBSERVATIONAL ESME PROGRAM

A. Francois¹, **A. Lusque**², C. Levy³, B. Pistilli⁴, E. Brain⁵, D. Pasquier⁶, M. Debled⁷, J.C. Thery⁸, A. Gonçalves⁹, I. Desmoulins¹⁰, T. de La Motte Rouge¹¹, C. Faure¹², J. Ferrero¹³, J. Eymard¹⁴, M.A. Mouret Reynier¹⁵, T. Petit¹⁶, O. Payen¹⁷, L. Uwer¹⁸, S. Guiu¹⁹, J. Frenel²⁰
[Lire](#)

ESR1 MUTATIONS AND OUTCOMES IN BRCA1/2 OR PALB2 GERMLINE MUTATION CARRIERS RECEIVING FIRST LINE AROMATASE INHIBITOR + PALBOCICLIB (AI+P) FOR METASTATIC BREAST CANCER (MBC) IN THE PADA-1 TRIAL

J. Frenel¹, **F. Dalenc**², B. Pistilli³, T. de La Motte Rouge⁴, C. Levy⁵, M. Mouret-Reynier⁶, A. Hardy-Bessard⁷, N. Bonichon-Lamichhane⁸, C. Greilsamer⁹, V. Delecroix¹⁰, S. Nguyen¹¹, F. Berger¹², S. Everhard¹³, J. Lemonnier¹⁴, D. Loirat¹⁵, C. Callens¹⁶, **A. Pradines**¹⁷, T. Bachelot¹⁸, S. Delaloge¹⁹, F.C. Bidard²⁰
[Lire](#)

AUTOIMMUNE DISEASES IN CENTRALLY REVIEWED THYMIC EPITHELIAL TUMOURS (TET)

J.C. Benitez Montanez¹, M. Boucher¹, E. Dansin², M. Kerjoun³, **J. Mazieres**⁴, E. Pichon⁵, F. Thillays⁶, P.E. Falcoz⁷, B. Roch⁸, Y. Oulkhouir⁹, F. Calcagno¹⁰, L. Thiberville¹¹, C. Clément-Duchêne¹², F. Morin¹³, P. Missy¹⁴, P.A. Thomas¹⁵, J. Maury¹⁶, T. Molina¹⁷, N. Girard¹⁸, B. Besse¹⁹

[Lire](#)

IFCT-1602 CHIVA2 PHASE II TRIAL: NIVOLUMAB IN PREVIOUSLY TREATED HIV-PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

A. Lavole¹, **J. Mazieres**², S. Schneider³, S. Brosseau⁴, L.M. Kiakouama⁵, L. Greillier⁶, A. GUIHOT⁷, B. Abbar⁷, M. Baron⁸, A. Makinson⁹, A. Langlais¹⁰, F. Morin¹¹, J. Spano¹², J. Cadranel¹

[Lire](#)